Epcoritamab Could Provide Active and Accessible Treatment Option for R/R LBCL

Chan Cheah, MBBS, FRACP, FRCPA, DMSc, discusses key safety and efficacy data from the EPCORE NHL-1 trial that may serve to support the approval of epcoritamab in patients with relapsed or refractory large B-cell lymphoma, and highlighted ongoing research efforts seeking to further move the needle forward in this disease.

Related Keywords

Perth ,Western Australia ,Australia ,Australian ,Chan Cheah ,Blood Cancer Research ,Department Of Internal Medicine ,Australian Cooperative Cancer Group ,Fellowship Program ,University Of Western Australia Wa Medical School ,Prescription Drug User Fee Act ,Fellowship Program Director ,Sir Charles Gairdner ,Internal Medicine ,Medical School ,Australian Cooperative Cancer ,Non Hodgkin Lymphoma ,News ,Nhl ,